Rapamycin and Tesamorelin Interaction: Monitor | Peptide Database

Join others researching Metformin — share findings, ask questions, and learn from real experiences Metformin is a biguanide compound and the most widely prescribed oral medication for type 2 diabetes mellitus worldwide, with over 150 million prescriptions annually. Originally derived from the French lilac (Galega officinalis), metformin was introduced in clinical practice in the 1950s in Europe and received FDA approval in the United States in 1995. Beyond its well-established role in glucose regulation, metformin has attracted significant attention in longevity and aging research. The Targeting Aging with Metformin (TAME) trial, a landmark multi-center study, is investigating whether metformin can delay the onset of age-related diseases in non-diabetic older adults. Observational data have suggested that diabetic patients taking metformin may have lower all-cause mortality than age-matched non-diabetic controls, prompting serious scientific interest in its potential geroprotective properties. Metformin exerts its primary effects through activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. AMPK activation triggers a cascade of downstream metabolic improvements: enhanced glucose uptake in skeletal muscle, suppression of hepatic gluconeogenesis, improved mitochondrial function, and increased fatty acid oxidation. Metformin also inhibits Complex I of the mitochondrial electron transport chain, which contributes to its AMPK-activating effects by increasing the AMP-to-ATP ratio. Beyond glucose metabolism, metformin modulates several pathways implicated in aging, including inhibition of mTOR signaling (a key regulator of cellular growth and senescence), reduction of oxidative stress and reactive oxygen species, attenuation of chronic low-grade inflammation via NF-kB pathway suppression, and activation of autophagy. These pleiotropic mechanisms underpin both its antidiabetic efficacy and its potential as an anti-aging compound.

Join others researching Vesilute — share findings, ask questions, and learn from real experiences Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium. Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.